Boreal Biomanufacturing

The Ottawa Hospital’s Biotherapeutics Manufacturing Centre (BMC), a facility that has developed more than 20 distinct cell- and virus-based products for human clinical trials in Canada, the United States, Europe and Asia, is now Boreal Biomanufacturing (Boreal).  

The change is part of a major initiative to expand Boreal’s role as a national and global biomanufacturing centre of excellence and signals a commitment towards advancing novel treatments for cancer and complex diseases. 

As an early-phase, non-profit contract development and manufacturing organization (CDMO) serving both commercial clients and academic researchers, Boreal pioneered the development of oncolytic cancer-fighting viruses and the first made-in-Canada CAR-T therapy, while also developing innovative regenerative stem-cell therapies and viral vectors for gene therapy. Boreal has fostered the development and successful launch of multiple advanced therapy biotech start-ups. 

Boreal continues to be owned and operated by The Ottawa Hospital and its expansion is critical to the hospital’s goal of reshaping the future of health care.